TAIHO PHARMA

Exploring hidden
possibilities for
people awaiting
new medicines

We mourn the loss of those who have died from COVID-19, extend our sympathies to their loved ones, wish COVID-19 survivors rapid and permanent recoveries, and express our gratitude to medical professionals and others who support the ill.

About Taiho

Becoming a truly global specialty pharma that meets the expectations of patients worldwide.

Our Business

Taiho Pharmaceutical creates innovative, highly valuable new drugs to support patients and the advancement of medicine, seeking to contribute to smiles and health for people all around the world.

News Releases

January 15, 2021

Taiho Pharmaceutical Announces Establishment of a New Company as a Clinical Development and Commercial Base in Switzerland
January 13, 2021

Taiho and Astex Extend Strategic Oncology Collaboration with MSD
Granting Exclusive License to SHP2 Program
January 12, 2021

Taiho Pharmaceutical Fully Adopts Carbon-Neutral Electricity at Saitama Site（PDF：127.2 KB）
January 05, 2021

Taiho Pharmaceutical Begins Phase III Clinical Trial with Therapeutic Drug for Duchenne Muscular Dystrophy (TAS-205) in Japan
December 17, 2020

Taiho Pharmaceutical Concludes Licensing of Automated PDPS Platform with PeptiDream

Information

July 12, 2018

Announcement of Support from Otsuka Holdings and Its Group Companies in the Aftermath of Severe Storms in Japan（PDF：165.9 KB）

Taiho Oncology
TAIHO PHARMA SINGAPORE
Otsuka Holdings
Otsuka Group's CSR